14 August 2013
: Case report
L-asparaginase fatal toxic encephalopathy during consolidation treatment in an adult with acute lymphoblastic leukemia
Unknown etiology, Unusual or unexpected effect of treatment, Unexpected drug reaction
Frantzeska FrantzeskakiABCDEFG, Michalis RizosABCD, Matilda PapathanassiouABC, Nikitas NikitasABC, Maria LerikouAB, Apostolos ArmaganidisAB, George DimopoulosABDOI: 10.12659/AJCR.889268
Am J Case Rep 2013; 14:311-314
Abstract
Background: Novel therapies have improved survival in malignancies of lymphoid origin. This improvement, however, has been at the cost of chemotherapy-related toxicities. L-asparaginase is frequently included in combination chemotherapies for acute lymphoblastic leukemia. Its use is frequently limited by significant adverse effects, such as coagulation abnormalities and cerebrovascular complications. L-asparaginase-associated encephalopathy is most often observed during the induction phase of chemotherapy and usually carries a favorable prognosis.
Case Report: We describe the profile of an adult with acute lymphoblastic leukemia treated with L-asparaginase, who developed toxic leukoencephalopathy during the second phase of consolidation treatment. He presented with decreased level of consciousness, which progressed to deep coma and finally brain death. MRI disclosed extensive lesions, consistent with toxic encephalopathy.
Conclusions: Even mild neurological symptoms should raise suspicion of these possibly fatal chemotherapy related toxicities.
Keywords: toxic encephalopathy, L-asparaginase, Leukemia
In Press
Case report
Am J Case Rep In Press; DOI: 10.12659/AJCR.946588
Case report
Am J Case Rep In Press; DOI: 10.12659/AJCR.946011
Case report
Am J Case Rep In Press; DOI: 10.12659/AJCR.945910
Case report
Am J Case Rep In Press; DOI: 10.12659/AJCR.945852
Most Viewed Current Articles
21 Jun 2024 : Case report
88,859
DOI :10.12659/AJCR.944371
Am J Case Rep 2024; 25:e944371
07 Mar 2024 : Case report
50,114
DOI :10.12659/AJCR.943133
Am J Case Rep 2024; 25:e943133
20 Nov 2023 : Case report
25,398
DOI :10.12659/AJCR.941424
Am J Case Rep 2023; 24:e941424
18 Feb 2024 : Case report
22,663
DOI :10.12659/AJCR.943030
Am J Case Rep 2024; 25:e943030